Infliximab

Children with Cogan’s syndrome should undergo thorough evaluations upon presentation, including screenings for autoimmune and infectious diseases, as well as echocardiography and brain MRI, according to data.

Infliximab was found to be safe and effective as adjunctive therapy for patients with central nervous system tuberculosis, researchers reported.

What concept represents the most important and transformational article ever written in all of rheumatology?

CHICAGO — Subcutaneous maintenance therapy with an infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe Crohn’s disease.

CHICAGO — Patients who underwent ileocecal resection for Crohn’s disease had a 33% lower risk for hospitalization, repeat surgery, systemic corticosteroid exposure and perianal CD, according to a presenter at Digestive Disease Week.

Combination therapy with adalimumab plus low-dose methotrexate induced a two-fold reduction of treatment failure among pediatric patients with Crohn’s disease, according to research published in Gastroenterology.

Subcutaneous infliximab achieved greater clinical remission and endoscopic response rates compared with placebo in patients with inflammatory bowel disease and has potential to become a more convenient, “patient-centric” treatment option.

Mandatory switching policies for biosimilars are “much more” effective in increasing adoption than focusing on new start strategies, according to a study of Canadian health spending data published in Arthritis Care & Research.

In this Healio video, Marla Dubinsky, MD, chief of pediatric gastroenterology at Mount Sinai Kravis Children’s Hospital, discusses recent COVID-19 has impacted ulcerative colitis care.

Celltrion has submitted a biologics license application to the FDA for the consideration of a subcutaneous formulation of infliximab in the treatment of inflammatory bowel disease, according to a press release.